Medimaps Group
announced that a novel method for improving osteoporotic fracture
risk assessment, TBS iNsight®, is now globally available to
clinicians through a distribution partnership with General Electric Healthcare
(NYSE: GE). GE Healthcare provides transformational medical technologies and
services to meet the demand for increased access, enhanced quality and more
affordable healthcare around the world and is the market leader in the development
and manufacture of Dual Energy X-Ray Absorptiometry (DXA) bone densitometry
systems.
On June 10, 2014, Medimaps Group –
developers of the TBS iNsight® diagnostic tool – and General
Electric Healthcare signed a distribution agreement to distribute TBS
iNsight® on a global basis leveraging GE Healthcare’s extensive
direct sales and distribution organization.
TBS iNsight® is a unique,
easy-to-use software application that assesses bone texture - an index of bone
microarchitecture – which in turn is expressed as the Trabecular Bone Score
(TBS). The measurement is performed seamlessly using DXA images acquired from a
bone mineral densitometry (BMD) scan. No additional patient scan time or
radiation exposure is required and results are easily interpreted by physicians
to enable them to better manage patients with high risk of fractures. TBS
iNsight® has been cleared for marketing by the U.S. Food and Drug
Administration.
Prof. Didier Hans, Chairman and
Chief Executive Officer of Medimaps Group states; “It is well documented that
40-50% of osteoporotic fracture occurs in patients who are not determined to be
osteoporotic by BMD alone, yet BMD remains the only diagnostic method available
to most clinicians. A significant body of literature, including a recent study
of over 29,000 women, has demonstrated that TBS, when combined with hip and/or
spine BMD and FRAX® clinical factors, can help improve the
prediction of future osteoporotic fracture risk in a clinically meaningful way.
We’re very pleased to partner with General Electric Healthcare to bring this
valuable new predictive tool for better management of osteoporotic patients
across the globe.”
For more information on Medimaps and
TBS iNsight®, please visit www.medimapsgroup.com and www.tbsinsight.com
About Medimaps Group
Medimaps group – a Swiss company
founded by a group of clinical practitioners and researchers - is a developer
of innovative imaging software used in clinical practice for improved patient
management with minimum impact on the workflow of the practitioner. The company
has raised several rounds of venture capital to further commercialize TBS
iNsight® in the osteoporosis treatment market and for product
development of the TBS iNsight® tool for optimizing implant surgery
in the dental and orthopedic markets.
Contacts
Medimaps Group
Oscar Lazaro, +1 781-492-2012
Chief Commercial Officer
olazaro@medimapsgroup.com
Oscar Lazaro, +1 781-492-2012
Chief Commercial Officer
olazaro@medimapsgroup.com
No comments:
Post a Comment